✦ LIBER ✦

What clinicians need to know about antioestrogen resistance in breast cancer therapy

✍ Scribed by Amalia Milano; Lissandra Dal Lago; Christos Sotiriou; Martine Piccart; Fatima Cardoso

Book ID: 116429100
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 385 KB
Volume: 42
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2006.06.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Do phytoestrogens reduce the risk of bre

Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know

✍ Louiza S. Velentzis; Jayne V. Woodside; Marie M. Cantwell; Anthony J. Leathem; M 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 223 KB

Partnering with patients: what doctors n

Partnering with patients: what doctors need to know about patient experience of advanced breast cancer

✍ Tamara Hamlish; Eve Elting; Dikla Benzeevi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Lifestyle interventions in breast cancer

Lifestyle interventions in breast cancer – what do we know and what do we need to know?

✍ P.J. Goodwin 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Text level reading comprehension in apha

Text level reading comprehension in aphasia: What do we know about therapy and what do we need to know?

✍ Webster, Janet; Morris, Julie; Connor, Carli; Horner, Rachel; McCormac, Ciara; P 📂 Article 📅 2013 🏛 Taylor and Francis Group 🌐 English ⚖ 216 KB

Existing data on breast cancer in Africa

Existing data on breast cancer in African-American women : What we know and what we need to know

✍ Christina A. Clarke; Dee W. West; Brenda K. Edwards; Larry W. Figgs; Jon Kerner; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB 👁 3 views

## Background: Much of what is known about breast cancer in african-american (aa) women is based on existing cancer surveillance data. thus, it is important to consider the accuracy of these resources in describing the impact of breast cancer in aa populations. ## Methods: National cancer surveil

Adjuvant trastuzumab therapy for HER2-ov

Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: What we know and what we still need to learn

✍ Martine J. Piccart-Gebhart 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 119 KB